<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01805804</url>
  </required_header>
  <id_info>
    <org_study_id>01/2012</org_study_id>
    <secondary_id>KNW-1-154/P/2/0</secondary_id>
    <nct_id>NCT01805804</nct_id>
  </id_info>
  <brief_title>Valsartan to Prevent Left Ventricle Remodeling in Pacemaker Patients</brief_title>
  <official_title>Randomized, Placebo Controlled Blinded Study to Assess the Efficacy of Valsartan to Prevent Left Ventricle Remodeling in Patients With Dual Chamber Pacemaker</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Silesia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Polpharma Pharmaceutical Company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Silesia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dual chamber pacing is known to induce left ventricle remodeling and may eventually lead to
      heart failure. The investigators aim to test hypothesis that valsartan started immediately
      after dual chamber pacemaker implantation will prevent left ventricle remodeling in twelve
      months long follow up in comparison with placebo. Echocardiographic assessment of left
      ventricle remodeling will be correlated with plasma activity of matrix metalloproteinases and
      their tissue inhibitors, indices of functional capacity such as plasma level of NTproBNP and
      distance in meters during six minute walking test.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in echocardiographically assessed left ventricle dimensions and left ventricle function</measure>
    <time_frame>baseline and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in plasma level of matrix metalloproteinase 9</measure>
    <time_frame>baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in plasma level of NTproBNP</measure>
    <time_frame>baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in atrial arrhythmia burden assessed from pacemaker memory</measure>
    <time_frame>baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in the rate of occurrence of any major adverse cardiovascular event</measure>
    <time_frame>2 weeks, 3 months, 6 months, 9 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in plasma level of tissue necrosis factor alpha</measure>
    <time_frame>baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in plasma level of tissue inhibitor of matrix metalloproteinase 3</measure>
    <time_frame>baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in distance walked during six minute walking test</measure>
    <time_frame>baseline and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>First Time Dual Chamber Pacemaker Implantation</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pills to match valsartan tablets administered once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>valsartan 80mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Valsartan 80mg tablet once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>valsartan 160mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Valsartan 160mg tablet once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo/valsartan</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>valsartan 80mg daily</arm_group_label>
    <arm_group_label>valsartan 160mg daily</arm_group_label>
    <other_name>Valsartan</other_name>
    <other_name>Other names:</other_name>
    <other_name>Diovan</other_name>
    <other_name>Axudan</other_name>
    <other_name>Vanatex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  informed written consent

          -  age ≥ 18 years

          -  first time pacemaker implantation for trifascicular block, atrioventricular second or
             third degree block

          -  left ventricle ejection fraction ≥ 40%

        Exclusion Criteria:

          -  significant valvular heart disease

          -  ischaemic heart disease requiring further revascularization

          -  symptomatic hypotension

          -  orthostatic disorders

          -  pregnancy, breast feeding, child bearing potential

          -  previous use of angiotensin receptor blocking agents

          -  known hypersensitivity to valsartan

          -  significant liver disorders

          -  significant renal disorders, including renal artery stenosis

          -  hyperaldosteronism

          -  chronic use of nonsteroid antiinflammatory drugs

          -  chronic use of lithium salts

          -  Patient's reluctance or disability to obey protocol and/or follow the scheduled visits

          -  any significant disease to reduce the expected life duration &lt; 12 months

          -  participation in any other trial within the last 30 days before randomization

          -  any situation that would put more risk on patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ewa Nowalany-Kozielska, MD PhD Associate Professor</last_name>
    <role>Study Director</role>
    <affiliation>Medical University of Silesia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beata Bialkowska, MD</last_name>
    <phone>0048323732372</phone>
    <email>beata.bialkowska@sum.edu.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>II Dept. of Cardiology in Zabrze Medical University of Silesia</name>
      <address>
        <city>Zabrze</city>
        <state>Upper Silesia</state>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrzej R Tomasik, MD PhD FESC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Beata Bialkowska, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wojciech Jachec, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Celina Wojciechowska, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Damian Kawecki, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katarzyna Wozniak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Grzegorz Banasik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Suzuki H, Geshi E, Nanjyo S, Nakano H, Yamazaki J, Sato N, Tanaka K, Takano T, Yagi H, Shibata T, Mochizuki S, Katagiri T. Inhibitory effect of valsartan against progression of left ventricular dysfunction after myocardial infarction: T-VENTURE study. Circ J. 2009 May;73(5):918-24. Epub 2009 Apr 2.</citation>
    <PMID>19346662</PMID>
  </reference>
  <reference>
    <citation>Miyazaki S, Kasai T, Miyauchi K, Miyazaki T, Akimoto Y, Takagi A, Aihara K, Kawamura M, Suwa S, Kojima S, Sumiyoshi M, Daida H. Changes of matrix metalloproteinase-9 level is associated with left ventricular remodeling following acute myocardial infarction among patients treated with trandolapril, valsartan or both. Circ J. 2010 Jun;74(6):1158-64. Epub 2010 Apr 6.</citation>
    <PMID>20378999</PMID>
  </reference>
  <reference>
    <citation>García RA, Brown KL, Pavelec RS, Go KV, Covell JW, Villarreal FJ. Abnormal cardiac wall motion and early matrix metalloproteinase activity. Am J Physiol Heart Circ Physiol. 2005 Mar;288(3):H1080-7. Epub 2004 Oct 14.</citation>
    <PMID>15486029</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2013</study_first_submitted>
  <study_first_submitted_qc>March 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2013</study_first_posted>
  <last_update_submitted>January 1, 2017</last_update_submitted>
  <last_update_submitted_qc>January 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Silesia</investigator_affiliation>
    <investigator_full_name>Andrzej Tomasik MD PhD FESC</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>dual chamber pacing, left ventricle remodeling, valsartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ventricular Remodeling</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

